ALKERMES | ALKS - Current Liabilities

Stock Price
34.32
Daily Change
-0.64 -1.83%
Monthly
22.57%
Yearly
9.65%
Q1 Forecast
32.88

ALKERMES reported $474.36M in Current Liabilities for its fiscal quarter ending in September of 2025.





Current Liabilities Change Date
AbbVie USD 39.39B 376M Sep/2025
Acadia Pharmaceuticals USD 356.58M 26.56M Sep/2025
ALKERMES USD 474.36M 31.6M Sep/2025
Amgen USD 21.79B 1.32B Sep/2025
Biogen USD 3.29B 106.3M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 40.14B 1.12B Sep/2025
Gilead Sciences USD 12.3B 1.11B Sep/2025
Ionis Pharmaceuticals USD 903.46M 6.22M Sep/2025
J&J USD 50.87B 3.31B Sep/2025
Malin Corporation EUR 1000K 500K Dec/2024
Merck USD 28.63B 2.59B Sep/2025
Neurocrine Biosciences USD 638M 91.7M Sep/2025
Otsuka Holdings JPY 698.27B 22.44B Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
Regeneron Pharmaceuticals USD 4.43B 758.1M Sep/2025
Vertex Pharmaceuticals USD 4.48B 336.9M Sep/2025